Extended Data Figure 3: CRISPR–Cas9-mediated knockout of CMTM6 reduces cell surface PD-L1 expression in a broad range of cancer cells.
From: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Flow cytometry analysis of cell surface PD-L1 in cells transduced with different sgRNAs targeting CMTM6 compared to parental Cas9-expressing cells. Cell lines depicted are melanoma (A375 and WM-852), triple-negative breast cancer (MDA-MB-231), non-small cell lung cancer (HCC-827) and pancreatic cancer (BxPC-3). All cells were pre-treated with IFNγ 500 IU ml−1 for 48 h before analysis. Selected representative histograms are presented in Fig. 1e.
